OM002
Phase 2- Indications
- Irritable bowel syndrome with constipation, Irritable bowel syndrome with diarrhea, Inflammatory bowel disease, Autism spectrum disorder
Company intelligence / Profile preview
Intrinsic Medicine
Seattle, Washington, United Statesintrinsicmedicine.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Intrinsic Medicine is advancing a pipeline of HMO-based medicines, with a lead candidate OM002 for IBS-C. The company is preparing for Phase 2 clinical trials.
- Therapeutic areas
- ImmunologyPsychiatryDermatologyRheumatologyGastroenterology
- Modalities
- Bioactive oligosaccharidesHuman Milk Oligosaccharides (HMOs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
IndieBioSOSVWRF CapitalDefine VenturesLink Ventures
Beyond the preview
Go deeper on Intrinsic Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intrinsic Medicine.